Indegene announced the strategic acquisition of BioPharm Communications, a specialised marketing services agency, to expand its commercialisation portfolio with AdTech, AI and digital advertising. The acquisition was done by ILSL Inc., a subsidiary of Indegene Limited, to strengthen its position in the data-driven omnichannel and media space. The acquisition comes at a time when US President Donald Trump has imposed 100% tariffs on patented and generic pharmaceuticals, which took effect yesterday, October 1. 

Founded in 2005, BioPharm’s clients include 17 of the world’s top 25 biopharma organisations. The agency would provide its expertise in omnichannel strategy, end-to-end media journey, and targeted engagement. The combination of Indegene and BioPharm would bring together vast data assets that would lead to higher media ROI and enable more effective agentic operations.

“BioPharm has built an impressive growth flywheel, with advanced tech capabilities, deep therapeutic expertise, and long-standing client relationships. This acquisition reinforces our position as the preferred tech-native, commercialisation partner for the life sciences industry, helping clients unlock greater strategic value from their marketing and AdTech investments”, said Manish Gupta, Chairman and CEO, Indegene.

“I am delighted to welcome Steve and the BioPharm team to the Indegene family, and we look forward to shaping the future of AI-led commercialisation together.” Indegene is a natural home for us, given their client-focused, innovation-first, employee-centric culture - backed by strong technology platforms, data and analytics capabilities, deep medical expertise, marquee client base and a global delivery model. And, we are very excited to join the larger Indegene family at a pivotal time for the industry”, said Steve Carickhoff, President, BioPharm. 

Pharma companies are reworking their market models as regulations tighten and discerning HCP preferences. Traditional agencies are struggling to keep pace, pushing firms toward specialised, AI-driven providers. Indegene’s latest acquisition comes as pharmaceutical companies want to co-innovate future-ready commercialisation models with an AI-first/data-driven approach.

Seyfarth Shaw LLP represented Indegene in this transaction.